Cargando…

Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate

The limited efficacy of vaccines in hepatocellular carcinoma (HCC), due to the low frequency of tumor-infiltrating cytotoxic T lymphocytes (CTLs), indicates the importance of innate immune surveillance, which assists acquired immunity by directly recognizing and eliminating HCC. Innate Vγ9Vδ2 T cell...

Descripción completa

Detalles Bibliográficos
Autores principales: SUGAI, SHIORI, YOSHIKAWA, TOSHIAKI, IWAMA, TATSUAKI, TSUCHIYA, NOBUHIRO, UEDA, NORIHIRO, FUJINAMI, NORIHIRO, SHIMOMURA, MANAMI, ZHANG, RONG, KANEKO, SHIN, UEMURA, YASUSHI, NAKATSURA, TETSUYA
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809658/
https://www.ncbi.nlm.nih.gov/pubmed/26936487
http://dx.doi.org/10.3892/ijo.2016.3403
_version_ 1782423677505110016
author SUGAI, SHIORI
YOSHIKAWA, TOSHIAKI
IWAMA, TATSUAKI
TSUCHIYA, NOBUHIRO
UEDA, NORIHIRO
FUJINAMI, NORIHIRO
SHIMOMURA, MANAMI
ZHANG, RONG
KANEKO, SHIN
UEMURA, YASUSHI
NAKATSURA, TETSUYA
author_facet SUGAI, SHIORI
YOSHIKAWA, TOSHIAKI
IWAMA, TATSUAKI
TSUCHIYA, NOBUHIRO
UEDA, NORIHIRO
FUJINAMI, NORIHIRO
SHIMOMURA, MANAMI
ZHANG, RONG
KANEKO, SHIN
UEMURA, YASUSHI
NAKATSURA, TETSUYA
author_sort SUGAI, SHIORI
collection PubMed
description The limited efficacy of vaccines in hepatocellular carcinoma (HCC), due to the low frequency of tumor-infiltrating cytotoxic T lymphocytes (CTLs), indicates the importance of innate immune surveillance, which assists acquired immunity by directly recognizing and eliminating HCC. Innate Vγ9Vδ2 T cells have major histocompatibility complex-unrestricted antitumor activity and are activated by phosphoantigens, which are upregulated in cancer cells by the nitrogen-containing bisphosphonate, zoledronate (Zol). A better understanding of HCC susceptibility to Zol and downstream γδ T cell-mediated killing is essential to optimize γδ T cell-mediated immunotherapy. This study systematically examined the interactions between γδ T cells and Zol-treated HCC cell lines (HepG2, HLE, HLF, HuH-1, JHH5, JHH7, and Li-7) in vitro. All HCC cell lines expressed the DNAX accessory molecule-1 ligands, poliovirus receptor, and Nectin-2, and γδ T cell-mediated killing of these cells was significantly enhanced by Zol. Small interfering RNA-mediated knockdown of these ligands did not affect the susceptibility to γδ T cell lysis. This killing activity was partly inhibited by mevastatin, an inhibitor of the mevalonate pathway, and markedly reduced by a monoclonal antibody to γ- and δ-chain T cell receptor, indicating that this is crucial for Zol-induced HCC killing. In addition, Zol-treated HCC cell lines triggered γδ T cell proliferation and induced production of Th1 and Th2, but not Th17, cytokines. The Zol concentration that enhanced HCC cell susceptibility to γδ T cell killing was lower than that required to directly inhibit HCC proliferation. Thus, γδ T cells may be important effector cells in the presence of Zol, especially where there are insufficient number of cancer antigen-specific CTLs to eliminate HCC. Our in vitro data support the proposal that Zol-treatment, combined with adaptive γδ T cell immunotherapy, may provide a feasible and effective approach for treatment of HCC.
format Online
Article
Text
id pubmed-4809658
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-48096582016-04-06 Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate SUGAI, SHIORI YOSHIKAWA, TOSHIAKI IWAMA, TATSUAKI TSUCHIYA, NOBUHIRO UEDA, NORIHIRO FUJINAMI, NORIHIRO SHIMOMURA, MANAMI ZHANG, RONG KANEKO, SHIN UEMURA, YASUSHI NAKATSURA, TETSUYA Int J Oncol Articles The limited efficacy of vaccines in hepatocellular carcinoma (HCC), due to the low frequency of tumor-infiltrating cytotoxic T lymphocytes (CTLs), indicates the importance of innate immune surveillance, which assists acquired immunity by directly recognizing and eliminating HCC. Innate Vγ9Vδ2 T cells have major histocompatibility complex-unrestricted antitumor activity and are activated by phosphoantigens, which are upregulated in cancer cells by the nitrogen-containing bisphosphonate, zoledronate (Zol). A better understanding of HCC susceptibility to Zol and downstream γδ T cell-mediated killing is essential to optimize γδ T cell-mediated immunotherapy. This study systematically examined the interactions between γδ T cells and Zol-treated HCC cell lines (HepG2, HLE, HLF, HuH-1, JHH5, JHH7, and Li-7) in vitro. All HCC cell lines expressed the DNAX accessory molecule-1 ligands, poliovirus receptor, and Nectin-2, and γδ T cell-mediated killing of these cells was significantly enhanced by Zol. Small interfering RNA-mediated knockdown of these ligands did not affect the susceptibility to γδ T cell lysis. This killing activity was partly inhibited by mevastatin, an inhibitor of the mevalonate pathway, and markedly reduced by a monoclonal antibody to γ- and δ-chain T cell receptor, indicating that this is crucial for Zol-induced HCC killing. In addition, Zol-treated HCC cell lines triggered γδ T cell proliferation and induced production of Th1 and Th2, but not Th17, cytokines. The Zol concentration that enhanced HCC cell susceptibility to γδ T cell killing was lower than that required to directly inhibit HCC proliferation. Thus, γδ T cells may be important effector cells in the presence of Zol, especially where there are insufficient number of cancer antigen-specific CTLs to eliminate HCC. Our in vitro data support the proposal that Zol-treatment, combined with adaptive γδ T cell immunotherapy, may provide a feasible and effective approach for treatment of HCC. D.A. Spandidos 2016-02-19 /pmc/articles/PMC4809658/ /pubmed/26936487 http://dx.doi.org/10.3892/ijo.2016.3403 Text en Copyright: © Sugai et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
SUGAI, SHIORI
YOSHIKAWA, TOSHIAKI
IWAMA, TATSUAKI
TSUCHIYA, NOBUHIRO
UEDA, NORIHIRO
FUJINAMI, NORIHIRO
SHIMOMURA, MANAMI
ZHANG, RONG
KANEKO, SHIN
UEMURA, YASUSHI
NAKATSURA, TETSUYA
Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate
title Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate
title_full Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate
title_fullStr Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate
title_full_unstemmed Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate
title_short Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate
title_sort hepatocellular carcinoma cell sensitivity to vγ9vδ2 t lymphocyte-mediated killing is increased by zoledronate
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809658/
https://www.ncbi.nlm.nih.gov/pubmed/26936487
http://dx.doi.org/10.3892/ijo.2016.3403
work_keys_str_mv AT sugaishiori hepatocellularcarcinomacellsensitivitytovg9vd2tlymphocytemediatedkillingisincreasedbyzoledronate
AT yoshikawatoshiaki hepatocellularcarcinomacellsensitivitytovg9vd2tlymphocytemediatedkillingisincreasedbyzoledronate
AT iwamatatsuaki hepatocellularcarcinomacellsensitivitytovg9vd2tlymphocytemediatedkillingisincreasedbyzoledronate
AT tsuchiyanobuhiro hepatocellularcarcinomacellsensitivitytovg9vd2tlymphocytemediatedkillingisincreasedbyzoledronate
AT uedanorihiro hepatocellularcarcinomacellsensitivitytovg9vd2tlymphocytemediatedkillingisincreasedbyzoledronate
AT fujinaminorihiro hepatocellularcarcinomacellsensitivitytovg9vd2tlymphocytemediatedkillingisincreasedbyzoledronate
AT shimomuramanami hepatocellularcarcinomacellsensitivitytovg9vd2tlymphocytemediatedkillingisincreasedbyzoledronate
AT zhangrong hepatocellularcarcinomacellsensitivitytovg9vd2tlymphocytemediatedkillingisincreasedbyzoledronate
AT kanekoshin hepatocellularcarcinomacellsensitivitytovg9vd2tlymphocytemediatedkillingisincreasedbyzoledronate
AT uemurayasushi hepatocellularcarcinomacellsensitivitytovg9vd2tlymphocytemediatedkillingisincreasedbyzoledronate
AT nakatsuratetsuya hepatocellularcarcinomacellsensitivitytovg9vd2tlymphocytemediatedkillingisincreasedbyzoledronate